NovoCure Stock Price, News & Analysis (NASDAQ:NVCR)

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NVCR shares.
View NVCR analyst ratings or view top-rated stocks.

8 brokerages have issued 12-month target prices for NovoCure's shares. Their NVCR share price targets range from $25.00 to $51.00. On average, they anticipate the company's stock price to reach $45.29 in the next year. This suggests a possible upside of 254.6% from the stock's current price.
View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts.

NovoCure's stock was trading at $73.35 on January 1st, 2023. Since then, NVCR shares have decreased by 82.6% and is now trading at $12.77.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our NVCR earnings forecast.

NovoCure Limited (NASDAQ:NVCR) released its quarterly earnings results on Thursday, October, 26th. The medical equipment provider reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.05. The medical equipment provider had revenue of $127.30 million for the quarter, compared to analysts' expectations of $128.75 million. NovoCure had a negative net margin of 39.14% and a negative trailing twelve-month return on equity of 46.89%. NovoCure's quarterly revenue was down 2.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.25) EPS.

ETFs with the largest weight of NovoCure (NASDAQ:NVCR) stock in their portfolio include BlueStar Israel Technology ETF (ITEQ), VanEck Israel ETF (ISRA), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares U.S. Medical Devices ETF (IHI).First Trust Nasdaq Pharmaceuticals ETF (FTXH).

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy (VNOM), Roku (ROKU), Salesforce (CRM) and Block (SQ).

NovoCure's stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (14.94%), Baillie Gifford & Co. (6.38%), Morgan Stanley (1.02%), Palo Alto Investors LP (0.62%), Charles Schwab Investment Management Inc. (0.51%) and Northern Trust Corp (0.41%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends.

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.